Arch Biopartners Inc.
ACHFF
Rank in Stocks
#23154
Arch Biopartners Inc. is a biotechnology firm dedicated to devising... Arch Biopartners Inc. is a biotechnology firm dedicated to devising groundbreaking solutions for both medical and commercial applications. A significant focus for the company is the advancement of Metablok, a key therapeutic agent designed to address or avert dipeptidase-1 driven inflammation in critical organs such as the lungs, liver, and kidneys. This inflammatory response can lead to profound organ dysfunction or complete failure, particularly in conditions like sepsis and COVID-19. Moreover, Arch Biopartners is developing AB569, an experimental medication intended to combat antibiotic-resistant bacterial infections, primarily through topical application on wounds. Their innovative product pipeline also features Borg, a specialized peptide-solid surface interface developed to hinder biofilm formation and lessen material corrosion. Lastly, MetaMx involves synthetic compounds engineered to target the cells that initiate brain tumors and invasive glioma cells. The company's operations are based out of Toronto, Canada.
Share Price
$0.65206
Last synced: 2026-11-09
Market Cap
$45.22M
Change (1 day)
5.17%
Change (1 year)
-14.20%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Arch Biopartners Inc. (ACHFF)
Category
Healthcare
EPS for Arch Biopartners Inc. (ACHFF)
EPS as of June 2026 TTM: $-0.03
According to Arch Biopartners Inc.'s latest financial reports, its current EPS (TTM) is $-0.03. At the end of 2025 the company had an EPS of $-0.02, an increase over its 2024 EPS of $-0.05.
EPS history for Arch Biopartners Inc. from 2000 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.03 | 51.00% |
| 2025 | $-0.02 | -62.80% |
| 2024 | $-0.05 | 16.58% |
| 2023 | $-0.04 | 139.02% |
| 2022 | $-0.02 | 8.61% |
| 2021 | $-0.02 | -74.01% |
| 2020 | $-0.06 | 115.19% |
| 2019 | $-0.03 | -34.47% |
| 2018 | $-0.04 | 47.14% |
| 2017 | $-0.03 | 91.78% |
| 2016 | $-0.01 | 21.67% |
| 2015 | $-0.01 | 66.67% |
| 2014 | $-0.01 | 84.62% |
| 2013 | 0.00 | -44.29% |
| 2012 | $-0.01 | -22.22% |
| 2011 | $-0.01 | -93.82% |
| 2010 | $-0.15 | 55.56% |
| 2009 | $-0.09 | 721.05% |
| 2008 | $-0.01 | 48.05% |
| 2007 | $-0.01 | 2,466.67% |
| 2006 | 0.00 | -95.52% |
| 2005 | $-0.01 | -70.74% |
| 2004 | $-0.02 | 84.68% |
| 2003 | $-0.01 | 55.00% |
| 2002 | $-0.01 | -96.73% |
| 2001 | $-0.24 | 8.03% |
| 2000 | $-0.23 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -51,954.30% |
US
|
|
| $-7.07 | 23,310.60% |
US
|
|
| $-5.29 | 17,416.56% |
AU
|
|
| $12.88 | -42,749.34% |
BE
|
|
| $21.56 | -71,490.73% |
NL
|
Questions about Arch Biopartners Inc.'s earnings per share (EPS)
What is Arch Biopartners Inc.'s earnings per share (EPS)?
Arch Biopartners Inc.'s earnings per share (EPS) over the last twelve months is $-0.03, as of Jun 2026.
What was Arch Biopartners Inc.'s earnings per share (EPS) in 2025?
In 2025, Arch Biopartners Inc.'s earnings per share (EPS) was $-0.02, compared with $-0.05 in 2024.
How has Arch Biopartners Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Arch Biopartners Inc.'s earnings per share (EPS) was highest in 2025 ($-0.02) and lowest in 2020 ($-0.06).
How does Arch Biopartners Inc.'s earnings per share (EPS) compare with similar companies?
Arch Biopartners Inc.'s earnings per share (EPS) ($-0.03) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.